324 related articles for article (PubMed ID: 21722073)
1. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble urokinase plasminogen activator receptor (suPAR) in early pregnancy prior to clinical onset of preeclampsia.
Odden N; Henriksen T; Mørkrid L
Acta Obstet Gynecol Scand; 2012 Oct; 91(10):1226-32. PubMed ID: 22774918
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
6. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
Toldi G; Bekő G; Kádár G; Mácsai E; Kovács L; Vásárhelyi B; Balog A
Clin Chem Lab Med; 2013 Feb; 51(2):327-32. PubMed ID: 22718576
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
10. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
[TBL] [Abstract][Full Text] [Related]
11. Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.
Ivancsó I; Toldi G; Bohács A; Eszes N; Müller V; Rigó J; Vásárhelyi B; Losonczy G; Tamási L
PLoS One; 2013; 8(4):e60697. PubMed ID: 23565268
[TBL] [Abstract][Full Text] [Related]
12. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
13. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
[TBL] [Abstract][Full Text] [Related]
14. Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters.
Ventorp F; Gustafsson A; Träskman-Bendz L; Westrin Å; Ljunggren L
PLoS One; 2015; 10(10):e0140052. PubMed ID: 26451727
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase-type plasminogen activator receptor (suPAR) and interleukin-6 levels in hyperemesis gravidarum.
Desdicioglu R; Yildirim M; Kocaoglu G; Demir Cendek B; Avcioglu G; Tas EE; Sengul O; Erel O; Yavuz AF
J Chin Med Assoc; 2018 Sep; 81(9):825-829. PubMed ID: 29033107
[TBL] [Abstract][Full Text] [Related]
16. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
17. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS).
Şirinoğlu M; Soysal A; Karaaslan A; Kepenekli Kadayifci E; Yalındağ-Öztürk N; Cinel İ; Yaman A; Haklar G; Şirikci Ö; Turan S; Altınkanat Gelmez G; Söyletir G; Bakır M
J Infect Chemother; 2017 Jan; 23(1):17-22. PubMed ID: 27771157
[TBL] [Abstract][Full Text] [Related]
19. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory markers in the second trimester prior to clinical onset of preeclampsia, intrauterine growth restriction, and spontaneous preterm birth.
Haedersdal S; Salvig JD; Aabye M; Thorball CW; Ruhwald M; Ladelund S; Eugen-Olsen J; Secher NJ
Inflammation; 2013 Aug; 36(4):907-13. PubMed ID: 23471783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
